Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells

I Witte\textsuperscript{1,3}, S Altenhöfer\textsuperscript{1,3}, P Wilgenbus\textsuperscript{1}, J Amort\textsuperscript{1}, AM Clement\textsuperscript{2}, A Pautz\textsuperscript{1}, H Li\textsuperscript{1}, U Förstermann\textsuperscript{1} and S Horke*\textsuperscript{1}

Major contributors to atherosclerosis are oxidative damage and endoplasmic reticulum (ER) stress-induced apoptosis; both of which can be diminished by the anti-oxidative protein paraoxonase-2 (PON2). ER stress is also relevant to cancer and associated with anti-cancer treatment resistance. Hence, we addressed, for the first time, whether PON2 contributes to tumorigenesis and apoptotic escape. Intriguingly, we found that several human tumors upregulated PON2 and such overexpression provided resistance to different chemotherapeutics (imatinib, doxorubicine, staurosporine, or actinomycin) in cell culture models. This was reversed after PON2 knock-down. Remarkably, just deficiency of PON2 caused apoptosis of selective tumor cells per se, demonstrating a previously unanticipated oncogenic function. We found a dual mechanistic role. During ER stress, high PON2 levels lowered redox-triggered induction of pro-apoptotic CHOP particularly via the JNK pathway, which prevented mitochondrial cell death signaling. Apart from CHOP, PON2 also diminished intrinsic apoptosis as it prevented mitochondrial superoxide formation, cardioplin peroxidation, cytochrome c release, and caspase activation. Ligand-stimulated apoptosis by TRAIL or TNF\textsubscript{\alpha} remained unchanged. Finally, PON2 knock-down caused vast reactive oxygen species formation and stimulated JNK-triggered CHOP expression, but inhibition of JNK signaling did not prevent cell death, demonstrating the pleiotropic, dominating anti-oxidative effect of PON2. Therefore, targeting redox balance is powerful to induce selective tumor cell death and proposes PON2 as new putative anti-tumor candidate.

Keywords: paraoxonase; apoptosis; endoplasmic reticulum stress; mitochondria; oxidative stress; CHOP

Abbreviations: ALL, acute lymphoblastic leukemia; ATF, activating transcription factor; CHOP, C/EBP homologous protein (growth arrest/DNA-damage inducible gene 153, GADD153); CML, chronic myeloid leukemia; eIF2\textalpha, eukaryotic initiation factor 2\textalpha; ER, endoplasmic reticulum; IRE1, inositol requiring enzyme 1; JNK, c-Jun N-terminal kinase; NAC, N-acetyl cysteine; PERK, PKR-like ER kinase; PON, paraoxonase; ROS, reactive oxygen species; SOD, superoxide dismutase; TRAIL, Tumor Necrosis Factor Related Apoptosis Inducing Ligand; UPR, unfolded protein response; XBP, X-box binding protein

Received 03.11.10; accepted 18.11.10; Edited by M Federici
PON2 is one of three highly conserved members of the paraoxonase family of enzymes consisting of PON1, PON2, and PON3. In contrast to PON1 and PON3, PON2 is not present in serum lipoprotein fractions, but an intracellular protein found in almost every tissue, particularly at the perinuclear region, ER and mitochondria.6-8 Again contrasting with PON1, PON2 shows predominant lactonase activity.6-11 Natural substrates remain unknown albeit PON2, as part of the innate immune system, appears involved in the defense against infections by the human pathogen *Pseudomonas aeruginosa*.12-14 Paraoxonases are important detoxifying and anti-oxidative enzymes, which establishes their role in organophosphate poisoning, diabetes, obesity, cardiovascular diseases, and innate immunity.11,15 In mice, PON levels negatively correlated with atherosclerosis.16-18 Consistently, several studies demonstrated that PON2 protected macrophages, vascular and other cells against oxidative stress, whereas its downregulation reversed this effect.5,7,19 The cytoprotective effect of PON2 is well established. However, it is fully enigmatic how PON2 reduced apoptosis, whether this is restricted to certain pathways and what the pathophysiological relevance could be. These issues are addressed in this study.

Although neglected and not primarily addressing PONs, some (microarray) studies observed marked overexpression of PON2 in cancers, for example, in hepatocellular carcinoma,20 prostate carcinoma21 or lymphocytes infected with T-cell leukemia virus22 PON2 was also highly upregulated in gene expression profiling studies addressing pediatric acute lymphocytic leukemia (ALL).23 In another study, PON2 was among a small group of upregulated genes that characterized pediatric ALL patients with very poor outcome prognosis and the potential to prospectively identify patients who fail current therapeutic regimens.24 Interestingly, PON2 was also present in an outcome-specific gene expression signature that characterized chronic myeloid leukemia (CML) patients resistant to front-line therapeutic imatinib.25 Given the anti-apoptotic role of PON26,26 and the fact that apoptotic escape represents a major clinical complication, we asked whether PON2 overexpression contributes to cancer as it confers apoptosis resistance. This is the first report that investigates the expression of PON2 in various human tumor samples, its involvement in cancer cell signaling and impact on cytotoxicity of chemotherapeutics. Our results are of great importance, given that targeting of redox balance in tumors recently turned into an attractive and very potent tool in cancer therapy.

Results

PON2 is overexpressed in tumors and its knock-down causes death of selective tumor cells. PON2 overexpression, in contrast to its knock-down, diminished ER stress-induced cell death and prevented mitochondrial superoxide production.5,26-28 The latter regulates cytochrome c liberation from mitochondria5 and may thus, explain how PON2 counteracts atherosclerosis, for example, by protecting vascular cells and macrophages from cell death. However, potential drawbacks of this cytoprotective effect or diseases other than atherosclerosis have never been tested. Cancer appeared relevant, because effects such as that of PON2 are frequently exploited by tumors. Therefore, we analyzed PON2 cDNA levels in cancer survey panels covering > 430 different samples from various normal versus diseased tissues (Figure 1a). Although no augmented PON2 levels were observed in some cases, moderate overexpression (~1.5-fold) was seen in tumors of thyroid gland, prostate, pancreas, and testis. Higher PON2 levels were found in tumors from endometrium/uterus, liver, kidney, lymphoid tissues, or urinary bladder (~2-4-fold). An upregulation of PON2 and its relevance are supported by recent studies that found high PON2 levels in association with poor prognosis in cohorts of pediatric ALL23,24 or with imatinib resistance in CML patients.25 We next analyzed protein expression in selected lysates from pools of normal versus tumor tissues (Figure 1b). No upregulation was seen in spleen tumors, and a moderate PON2 overexpression in pancreas and lung tumors. In concordance with above cDNA panels, kidney and liver tumors doubled PON2 protein levels. Over 10-fold upregulation of PON2 was found in thymus tumors and non-Hodgkins lymphomas (the latter is 1.7-fold when normalized to lymph node instead of peripheral leukocytes).

We hypothesized that PON2 contributes to apoptotic escape of tumor cells and tested whether chemotherapeutic-triggered cell death correlated with its expression level. Indeed, stable overexpression of PON2-GFP or PON2-HA in endothelial cells reduced the dose-dependent activation of caspase-3 and intracellular ATP decrease in response to the anthracycline doxorubicin (Figure 1c). Similarly, increased PON2 levels prevented death of Bcr-Abl-positive K562 leukemia cells in response to front-line therapeutic imatinib, a Bcr-Abl kinase inhibitor (Figure 1d). This likely explains the contribution of PON2 to imatinib resistance in primary resistant CML patients.25 As PON2 upregulation provided apoptotic escape (Figures 1c and d and below), we tested whether PON2 deficiency reversed this effect to enhance susceptibility to chemotherapeutics. Indeed, RNAi-mediated knock-down of PON2 was even additive to imatinib-triggered K562 cell death and enhanced apoptosis rates (Figure 1e and Supplementary Figure s1A). Strikingly, however, we observed that just PON2 knock-down caused significant cell death even in the absence of pro-apoptotic stimulation (Figure 1e), which was unexpected given the viability of PON2-deficient mice. To expand this to other tumor cell lines, PON2 was knocked down in K562 leukemia cells, A549 lung carcinoma cells, endothelial EA.hy 926 cells, Huh7 and HepG2 hepatoma cells, embryonic kidney HEK293 cells, and Jurkat T-cell leukemia cells. We analyzed, 3 days later, apoptosis rates by flow cytometry (Figure 1f and Supplementary Figure s1A). Huh7 (or HepG2; not shown), Jurkat, and HEK293 cells did not react to PON2 knock-down. This contrasts with severely increased apoptosis of K562, A549, and EA.hy 926 cells. As apoptosis required no further stimulation to proceed, we revealed an unanticipated oncogenic role for PON2, apparently of special importance for leukemias or lung cancer. Therefore, we next addressed its mechanism.

PON2 reduces UPR-triggered induction of pro-apoptotic CHOP. Previous data linked PON2 with ER stress-induced cell death.5,20 To discriminate apoptotic pathways and reveal
underlying mechanism(s), we first tested PON2’s effect on transcriptional induction of CHOP, a very potent pro-apoptotic factor critically involved in ER stress (and below1). Naive or PON2-GFP overexpressing cells were challenged with tunicamycin to induce ER stress. Tunicamycin time-dependently increased CHOP mRNA and
protein levels, but this was substantially lower in PON2-overexpressing cells (Figures 2a and b). Given the impact of CHOP on cell death, this effect likely explains the protective role of PON2, at least in part and in response to ER stress. In order to test this hypothesis and because apoptotic efficacy of CHOP may relate to cell type and stimulus, CHOP was knocked down by siRNA (Figure 2c). Subsequently, we monitored tunicamycin-induced apoptotic processes. Figures 2d–f show that abrogated CHOP expression correlated with reduced levels of cardiolipin peroxidation, preserved mitochondrial membrane potential $\Delta \Psi M$, absent nuclear condensation, and low caspase-3 activation. Hence, CHOP is centrally involved in signaling from ER to mitochondria and a decrease of its induction, as resembled by high PON2 levels, is sufficient to avert ER stress-induced apoptosis.

PON2 has an enzymatic lactonase activity and it reduces oxidative stress. To distinguish which function diminished CHOP induction, we used PON2 point-mutations $H^{114}Q$ or $H^{132}Q$, as these blunted its lactonase, but not anti-oxidative activity. These PON2-mutants reduced CHOP induction and cell death indistinguishable from PON2-wildtype (see Figure 3a for CHOP and for caspase-3 activation, intracellular ATP levels and apoptosis). This discloses PON2’s anti-oxidative effect as basis for its anti-apoptotic function. Yet, there is no mutation known that abrogates PON2’s impact on ROS, so we verified that established anti-oxidative mechanisms also attenuated CHOP expression. Naïve cells were loaded with cell-permeable superoxide dismutase (PEG-SOD; 100 U/ml) or N-acetyl cysteine (NAC; 10 mM) 24 h before addition of tunicamycin. Both treatments diminished ROS production (not shown) and CHOP activation (Figures 3b and c), which confirms the impact of ROS secondary to ER stress.

PON2 reduces CHOP induction by lowering JNK signaling. We next addressed how PON2 decreased CHOP induction. First, we analyzed the c-Jun N-terminal kinase (JNK) pathway, because ER stress produces ROS that can activate JNK, which in turn can be upstream and downstream of the UPR and CHOP. Given that PON2 diminished ER stress-induced ROS and because anti-oxidants lowered CHOP induction (and above), we suggested that PON2 decreased CHOP by acting on ROS-activated JNK. Indeed, tunicamycin-triggered JNK activation (i.e., Thr$^{183}$/Tyr$^{185}$ phosphorylation) was significantly lower in PON2-overexpressing cells (Figure 3d). Consequently, we verified that JNK inhibition reduced CHOP expression in naïve but not PON2-overexpressing cells. This was assessed by pharmacological and genetic approaches. The JNK inhibitor SP600125 significantly lowered tunicamycin-triggered CHOP induction in naïve cells (Figure 3e), demonstrating that in this system JNK is upstream of CHOP expression. This effect was absent in PON2 overexpressing cells (Figure 3e). JNK knock-down by siRNA also decreased CHOP induction in naïve but not in PON2-overexpressing cells (Figure 3f and Supplementary Figure S1B). Concordantly, CHOP induction in naïve cells with SP600125 or JNK siRNA did not significantly differ from that in PON2-overexpressing cells without such stimulation.

Next, we verified the specificity of PON2 for the JNK-CHOP-axis. CHOP induction in response to ER stress is mainly mediated by activation of the three UPR branches transduced by IRE1, PERK, and ATF6. To determine PERK activation, we measured eIF2α phosphorylation and ATF4 induction. Figure 4a shows an increase in phospho-eIF2α levels 2 h after tunicamycin addition, which gradually increased over time. This was identical in naïve and PON2-overexpressing cells. Further, PON2 overexpression did not alter induction of ATF4 mRNA or protein (Figure 4b and not shown). In a similar manner, IRE1-mediated splicing of XBP1 mRNA was unaffected by PON2 overexpression (Figure 4c). Processing and thus activation of ATF6 by Site-1 and Site-2 proteases was also independent from PON2 levels (Figure 4d). Hence, we demonstrate that PON2 overexpression counteracts cell death by balancing ROS levels. During ER stress, this holds CHOP at bay and could be achieved as PON2 via ROS controls JNK activation (and not by acting on PERK, IRE1, or ATF6 signaling). In agreement with such model, PON2 knock-down is sufficient to induce vast ROS production (Figure 5a). Still in accord, it also causes moderate CHOP expression (Figure 5b), however, viability loss after PON2 knock-down is not prevented by inhibited JNK signaling (Figure 5c), which reveals that additional effects (disturbed mitochondrial redox homeostasis; see below) dominate over the induction of CHOP.

PON2 also protects against intrinsic apoptotic signaling. We next assessed PON2’s effect on ER stress-unrelated apoptosis. To this end, cells were treated with additional chemotherapeutics and established inducers of intrinsic apoptosis, such as PKC inhibitor staurosporine or transcription inhibitor actinomycin D. These compounds failed to induce CHOP (Supplementary Figure S1C), so effects are independent from this protein. Staurosporine treatment (0.5 μM; 16 h) caused pronounced apoptosis in naïve cells (~77%), which was strongly reduced in PON2-overexpressing cells (~33%; Figure 6a). A closely similar tendency was seen after actinomycin D treatment (5 μg/ml; 24 h; Figure 6a). Given the protection afforded by higher PON2 levels, we traced upstream effects and monitored
PON2 confers apoptosis resistance to cancer cells

I Witte et al.

Cell Death and Disease
caspase signaling. As expected, activation of caspases 8, 9, and 3 in response to these treatments was significantly lower in PON2-overexpressing cells (Figure 6b).

Confocal microscopy of live cells revealed that PON2 signals overlapped with both ER and mitochondria (Supplementary Figure S2), which confirms previous biochemical approaches and also more recent data reporting individual mitochondrial PON2 functions.6,27,28 Because mitochondria can be crucial to apoptosis and upstream of caspases, we applied a FACS-based approach to test whether PON2 affected cytochrome c release. Staurosporine induced a dose-dependent increase in mitochondrial cytochrome c liberation in naive cells (Figure 7a, left). This was substantially diminished in cells overexpressing PON2 (Figure 7a, right), which explains the reduced apoptosis rates described above. To address whether PON2 has direct mitochondrial functions or affects cytoplasmic caspase feedback loops, staurosporine-induced cytochrome c release was assessed in the presence of pan-caspase inhibitor, Z-VAD-fmk. This blocked caspases 8, 9, and 3/7, but did not prevent cytochrome c release (Supplementary Figure S3), suggesting that PON2 functions at the mitochondria.

We next analyzed peroxidation of cardiolipin, a lipid at the inner mitochondrial membrane that critically controls cytochrome c release.31 Staurosporine dose-dependently caused cardiolipin peroxidation in naive cells, whereas PON2-overexpressing cells were substantially more resistant (Figure 7b).

Cardiolipin peroxidation is preceded by excess mitochondrial O2/C02 generation. We finally demonstrate that PON2 counteracts such event: Cells with or without stable PON2-HA overexpression were labeled with Mito-HE (mitochondria-targeted dihydroethidium), treated with complex III-inhibitor antimycin A to induce O22, and analyzed by a fluorometer or FACS at wavelengths specific for O22-induced Mito-HE products. The pronounced accumulation of mitochondrial O22 observed in naive cells was significantly lower in

Figure 3  PON2 diminishes CHOP induction by lowering JNK activation. (a) Endothelial cells overexpressing PON2-WT-GFP or lactonase-deficient PON2-H1′4Q-GFP were treated with tunicamycin (1 μg/ml; 8 h) and analyzed for CHOP mRNA levels. (b and c) Naïve EA.hy cells were treated with PEG-SOD (100 U/ml) or NAC (10 mM) for 24 h before addition of tunicamycin and quantification of CHOP mRNA (b) or protein (c). (d) naïve or PON2-GFP overexpressing cells were tunicamycin-stimulated (1 μg/ml; 30 min) and analyzed for JNK-phosphorylation (fold increase shown below). GAPDH protein levels served as loading control. Similar results were obtained for other time points and in multiple experiments. (e) Indicated cells were treated with tunicamycin (1 μg/ml; 8 h) or JNK inhibitor SP600125 (10 μM) or both, followed by CHOP mRNA quantification. (f) Indicated cells treated with scrambled (Ctrl) or JNK-specific siRNA were stimulated with tunicamycin (1 μg/ml; 8 h), followed by CHOP mRNA quantification. Symbols represent mean ± S.E.M. n = 3–9; n.s. = not significant; *P < 0.05; **P < 0.01; ***P < 0.001
PON2-overexpressing cells (Figure 7c and Supplementary Figure S4A). Similarly, antimycin-treated mitochondria isolated from PON2-HA-overexpressing cells produced less O2 than those from controls (Supplementary Figure S4B). Two contemporary analyses revealed that PON2 prevents O2 production because of an interaction with coenzyme Q10.27,28 Also, PON2 wildtype and lactonase-deficient mutants were equally protective against intrinsic apoptosis.27 Thus, PON2 diminishes pro-apoptotic mitochondrial O2 bursts that prevent cardiolipin peroxidation, cytochrome c release, caspase activation, and cell death.

PON2 does not impact on extrinsic apoptotic pathways. In contrast to intrinsic apoptosis, PON2 failed to attenuate extrinsic signaling. This is demonstrated by the fact that PON2 did not alter any level of signal transmission in response to death receptor-dependent apoptosis by TRAIL, as documented by activation of caspase-8 after 2 h, caspase-3 after 6 h and cell death after 16 h (Figures 8a–c, respectively). PON2 also did not decrease caspase-3 activation in response to TNFα/actinomycin D co-treatment (Figure 8d). Hence, PON2 is ineffective when ligand-mediated stimuli are sufficiently strong to activate caspase-cascades at the receptor complex (type-1 cells). A schematic summary of PON2’s anti-apoptotic function is depicted in Supplementary Figure S5.

Discussion
Treatment of malignancies is often hampered because tumor cells modulate execution of the cell death program to promote apoptosis resistance, which contributes to failure of immunosurveillance and therapeutic approaches. This can be achieved by potentiation of anti-apoptotic or attenuation of pro-apoptotic signaling. The mechanistic insight provided in this study and the result that several tumors overexpress PON2, combined with the finding that PON2 deficiency destabilizes tumor cells, led us to propose PON2 as novel putative anti-tumor target.

PON2 overexpression significantly protected cells from oxidative stress and, more importantly, from ER stress-induced apoptosis.6,26 It was totally unsolved, however, how the diminished caspase activation was achieved and whether this was limited to ER stress. We here revealed that PON2 overexpression diminished the induction of pro-apoptotic CHOP. Further, we provide evidence that CHOP deficiency prevents cardiolipin peroxidation, loss of mitochondrial membrane potential, nuclear condensation and caspase activation in response to ER stress. Given these results and many other reports that demonstrate the fundamental role of CHOP,3,4,32 it is clear that reduced CHOP levels, as resembled by PON2 overexpression, contribute to cell survival. One thus may speculate whether the known antiatherogenic potential of PON218,33 results from its effect on CHOP, when considering its linkage to atherosclerosis.34
The UPR IRE1 branch is of particular importance, as it produces the spliced-XBP1 transcription factor and the IRE1/TRAF2/ASK1 signaling cascade, which both activate JNK and induce CHOP. Moreover, CHOP induction results from oxidative stress, which accompanies ER stress and appears upstream of XBP1 and/or JNK. Most likely owing to its anti-oxidative role during ER stress, PON2 reduces JNK activation and CHOP induction. Likewise, other studies revealed a reduced CHOP induction by anti-oxidative interventions. It remains undetermined what particular redox-sensitive pathway is altered by PON2 to reduce JNK phosphorylation, because this is beyond our scope and requires intense investigation in an entirely new though interesting project. It is a matter of debate that ROS sources are activated during ER stress and it is presently unknown whether PON2 reduces ROS only at the mitochondria, or perhaps also at the ER, or in conjunction, for example, with NADPH oxidases (as shown for NOX4 in TGF-β-stimulated smooth muscle cells). Similarly, multiple pathways link ROS with JNK activation, such as ASK1 (modulated by thioredoxin, glutaredoxin, PKD, or 14-3-3/PP5). Src kinase, Glutathione S-transferase Pi, RIP/TRAF2, or IRE1/TRAF2/ASK1. Therefore, a future challenge is to investigate these pathways and the relatedness to PON2 and to locate the precise generation of ROS. More straightforward, however, it is established that PON2 prevents the generation of mitochondrial superoxide, which controls subsequent apoptotic pathways similar to cardiolipin peroxidation and cytochrome c release.

Conceptual advance comes from our finding that PON2 modulates execution of the cell death program directly at the mitochondria, thereby allowing modification of several apoptotic pathways converging at these organelles. In this manner, we provide evidence for the first time that PON2’s effect is not limited to ER stress hence, it may be an interesting pharmacological target, be it to prevent either cell loss or apoptotic escape. Because PON2 amplifies an already existing reaction, it may not be confounded by targeting problems. Moreover, diminished apoptotic signaling is accomplished at an early step, that is, before a ‘point-of-no-return’ has been passed due to cardiolipin peroxidation and subsequent cytochrome c release. Large-scale analyses must address which specific tumors upregulate PON2, whether this is subtype and/or stage-specific and what pathways are involved. A simple explanation is that chromosome-7, which harbors the PON cluster, is amplified in several tumors, such as papillary renal kidney carcinoma cells or prostate adenocarcinomas. The urokinase plasminogen activator system may also be relevant, as this is increased in numerous cancers and upregulates PON2. Given that high basal PON2 levels did not correlate with high sensitivity to its knock-down, future studies should test larger tumor cell panels for PON2 deficiency-simulated cell death.

Our study revealed lacking protection by PON2 against receptor-triggered signaling. Upon ligand binding, the receptor recruits the Fas-associated death domain protein FADD, thereby forms the death-inducing signaling complex, which activates, for example, caspase-8. Because this sufficiently activates several other caspases, execution of apoptosis is unaltered, for example, by mitochondrial acting Bcl-2 proteins in so-called type-I cells; however, some receptor-triggered pathways also employ mitochondrial amplifier feed-back loops via Bid cleavage in type-II cells, which led to the proposal of two distinct but overlapping routes to cell death. In agreement, PON2 altered caspase-8 activation in response to staurosporine and actinomycin but not TRAIL. The fact that PON2 did not alter ligand-induced caspase activation or cell death argues against a role on receptor-triggered apoptosis in type-I cells.

Several studies demonstrated that PON2 deficiency predisposes to vascular complications and atherosclerosis. Likewise, PON2 may impact on diabetes, given the importance of ER stress, JNK signaling and CHOP expression for...
β-cell homeostasis. From such perspective, enhanced PON2 expression may be desirable. However, our results disclose that PON2 upregulation could be detrimental by supporting apoptosis escape and tumor development. Therefore, the pharmacological downregulation of PON2 in specific tumors may one day add to established cancer therapies.

Materials and Methods

Cell culture, plasmids, and material. Human endothelial EA.hy 926 cells were cultured in Dulbecco’s modified Eagle’s medium without Phenol Red (Sigma, St. Louis, MO, USA) containing sodium pyruvate (PAA Laboratories, Pasching, Austria), antibiotics penicillin/streptomycin, hypoxanthine/aminopterin/thymidine supplement, GlutaMAX (Invitrogen, Carlsbad, CA, USA) and 10% (v/v) fetal calf serum (Perbio, Thermo Fisher Scientific, Waltham, MA, USA). Stable cell lines, plasmids and transfection procedures were described before. HEK293, Jurkat, K562, and A549 cells were from the German Collection of Microorganisms and Cell Cultures. K562 and Jurkat cells were cultured in RPMI with phenol red (Sigma), 10% fetal calf serum, sodium-pyruvate, and penicillin / streptomycin. A549 received the same medium as EA.hy 926, but 5% serum. Cells were cultured at 37 °C in a humidified atmosphere under 5% CO2 (10% for EA.hy 926).

Staurosporine, tunicamycin, actinomycin D, antimycin A, polyethylene glycol (PEG)-conjugated SOD (PEG-SOD), doxorubicin, N-acetyl-cysteine, imatinib, and SP600125 were purchased from Sigma; Mito-HE was from Molecular Probes (Invitrogen / Life Technologies); TRAIL and TNFα were from Miltenyi Biotech. Plasmid p3xFLAG-ATF6 was cloned by R Prywes and is distributed as Addgene plasmid 11975.
Fractionation and western blotting. Unless otherwise indicated, tunicamycin was used with 1 μg/ml for 6 h; controls contained 0.5%, solvent (DMSO). To monitor ATF6 processing, cells grown in six wells were transfected with 0.25 μg p3xFLAG-ATF6 plus 1.5 μg pCDNA3 using Nanofectin (PAA). The low amount of FLAG-ATF6 ensured tight ER stress regulation. Mitochondria were isolated according to recently published procedures.27 Preparation of total protein lysates, SDS-PAGE, and western blotting using a semi-dry transfer system (Bio-Rad, Hercules, CA, USA) was performed as before.6,26 When phospho-antibodies were used, lysates contained Phospho-STOP (Roche, Basel, Switzerland). For analysis of CHOP and mitochondrial fractions, we performed tankblots using Bio-Rad’s Mini-Trans-Blot-System and PVDF membranes (Amersham, Chalfont St Giles, Great Britain, Hybond-P). Protein content was determined using the bicinchoninic acid protein assay reagent (Pierce, ThermoFisher Scientific). Immunodetected proteins were visualized by Western-Lightning chemiluminescence kit (Perkin Elmer, Waltham, MA, USA) using X-ray film exposure and were quantitatively evaluated with a ChemiDoc XRS imaging system (Bio-Rad) equipped with QuantityOne 4.6.7 software. All samples were quantitatively normalized to α-tubulin, glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and/or p38-MAPK.

Antibodies. We used the following antibodies: rabbit-anti-phospho-elF2α (Ser51), rabbit-anti-p38-MAPK, rabbit-anti-phospho-SAPK/JNK (Thr183; Tyr185) (Cell Signaling Technology, Danvers, MA, USA); rabbit-anti-ATF4, mouse-anti-GAPDH 6C5, rabbit-anti-CHOP F168, goat-anti-Lamin C-20 (Santa Cruz, Santa Cruz, CA, USA); mouse-anti-Flag M2 (Stratagene, Agilent Technologies, Santa Clara, CA, USA); mouse-anti-Complex III subunit core 2 (MitoSciences, Eugene, OR, USA); mouse-anti-Cytochrome c clone 7H8.2C12. (BD Biosciences, Franklin Lakes, NJ, USA); rabbit-anti-PON2;6 mouse-α-Tubulin Ab2 (Dianova, Hamburg, Germany); mouse-anti-hemagglutinin HA-7 (Sigma); HRP-conjugated secondary antibodies were from Sigma and Cell Signaling Technology.

qRT-PCR. RNA was isolated with PegGold RNA isolation kits from Peqlab. 80 ng of RNA was used for cDNA generation using High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Life Technologies, Carlsbad, CA, USA). RNA expression levels were quantitatively analyzed using 2 μl cDNA, 0.1 unit Go-Taq polymerase (Promega, Madison, WI, USA), 0.4 μl 10 mM dNTPs and
Figure 8  PON2 does not alter ligand-induced caspase activation. Naive or PON2-GFP overexpressing cells were treated with various concentrations of TRAIL and analyzed for caspase-8 activity after 2 h (a), or with 100 ng/ml TRAIL and analyzed for caspase-3/7 activity after 6 h (b), or 1 or 3 ng/ml TRAIL followed by determination of intracellular ATP levels after 16 h (c). We used low TRAIL doses in C, as higher concentrations killed cells too rapidly such that an overwhelming stimulus could have masked potential effects of PON2. (d) Named cells were treated for 16 h with TNF-a (10 ng/ml) or actinomycin D (1 \( \mu \)g/ml) or both; subsequently, caspase-3/7 activity was assessed. Symbols represent mean \( \pm \) S.E.M. \( n = 3 - 6 \) independent experiments (>duplicates each); n.s. = not significant; ***P<0.001.

20 pmol per primer per 20 \( \mu \)l reaction in a Bio-Rad Laboratories iCycler. The following Taqman primers (Eurofins MWG Operon) were used: GAPDH; sense 5'-CAACAGGCTCAAGATCATCAGC-3', antisense 5'-TGGCATGACCTGTTGA-3'; probe 5'-CCCTGCAAGAGGTCCTGTC-3'; CHOP: sense 5'-GA CCTGCAAGAGGCTCCTGTG-3', antisense 5'-CTCCTCCTCTCAGTCCAGCCAAG-3'; probe 5'-CACACACTCGTGCCTGTTT-3'; spliced-XBP1: sense 5'-GGGATGCTGAGAGCCATTG-3'; antisense 5'-TGGCATGGACTGTGGTCA-3'; probe 5'-AACTGAGCTGAGGAGCTTT-3'; GAPDH and p38-MAPK.

Detection of mitochondrial superoxide, membrane potential (\( \Delta \Psi M \)) and oxidative stress. Assessment of mitochondrial superoxide was recently described.\(^\text{27}\) To monitor \( \Delta \Psi M \), we used the fluorescent probe tetramethylrhodamine ethyl ester (TMRM) (Molecular Probes) and the fluorimeter Fluostar-Optima (BMG Labtech). Cells were stained with TMRM (1 \( \mu \)M) and oxidative stress was assessed by flow cytometry (see below; FITC filter set).

Detection of mitochondrial cytochrome c release. Cells grown in 12-well dishes were trypsinized, resuspended in growth medium, pelleted (350 \( \times \) g, 4 °C, 5 min), washed with chilled PBS and re-centrifuged, washed twice in chilled PBS, washed, suspended in growth medium and analyzed by confocal microscopy (see above) under constant conditions (i.e., laser power, gain, pixel dwell etc.). To detect oxidative stress, cells were treated with siRNA (see below), incubated for 2 to 3 days, washed with HBSS, labeled with 2.5 \( \mu \)M \( \text{cm}{H_2}D{C}{F}{DA} \) (Molecular Probes; 30 min; 37 °C), washed, detached, washed, suspended in HBSS, and analyzed by flow cytometry (see below; FITC filter set).

Cardiolipin peroxidation. Cardiolipin was measured by incubating cells with acridine orange 10-A-nonyl bromide (NAO; Invitrogen; 50 nM; 30 min; 37 °C), which only binds non-peroxidized cardiolipin. Then, cells were trypsinized, resuspended in complete growth medium, pelleted (350 \( \times \) g, 4 °C, 5 min), washed with PBS, re-centrifuged, fixed in 4% paraformaldehyde and analyzed by FACS. Alternatively, cells grown in 96-well plates were stained with NAO as before and analyzed by a Fluostar-Optima fluorimeter.

ATP content and caspase activity. To investigate intracellular ATP content, cells were seeded in opaque 96-well plates and treated next day with the indicated stimulus and duration. Then, the CellTiterGlo reagent (Promega) was used as recommended by the supplier. Alternatively, we used Caspase-Glo assays (Promega) according to the manufacturer’s protocol and previously published data acquisition.\(^\text{6}\)

RNA interference. Cells at 60% confluency were transfected with 50 nm PON2-specific siRNA (5'-TTGAGTATCCCTCCAGGCTTACTGG-3'; Invitrogen), 35 nm CHOP or JNK-specific smart-pool siRNAs (a mix of four different siRNAs each; Dharmacon, Thermo Fisher Scientific) or scrambled siRNA (Invitrogen) using a Fluori-Optima reagent (Synvolux, Groningen, Netherlands).

Flow cytometry. Cells were stained with annexin-V-phycocerythrin and 7-amino-actinomycin (apoptosis-detection-kit-I; BD Biosciences) as recommended by the manufacturer; 10,000 fluorescent events were acquired using a Facs-Calibur equipped with CellQuest Pro software (BD Biosciences).

Cancer survey panels. PON2 expression levels were determined in cancer versus normal tissues by quantitative real-time PCR using TissueScan Cancer Survey Panel-III (4 \( \times \) 96-well format) and Lymphoma Cancer Panel-II (Origene). Pre-normalized (beta-actin) cDNAs were solubilized (15 min on ice) in a 20 \( \mu \)l reaction mix consisting of 10 pmol per primer (see above) and the JumpStart Taq polymerase mix from Sigma. PON2 cDNA levels were quantified and normalized to those of GAPDH. See supplier’s homepage (http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx) for details on the tissues and comprehensive pathology reports. Real-time qPCR was performed in a Bio-Rad Laboratories iCycler. In order to address PON2 protein mass in cancer samples, pooled tumor, or normal tissue western blots were purchased from Assay Depot; PON2 was normalized to both GADPH and p3-MAKP.
Software, statistics and image acquisition. GraphPad Prism-5 was used for calculations, non-linear regression curve fitting or statistical evaluation using 1/2-way ANOVA with Bonferroni’s multiple comparisons post test (see Figure legends). P < 0.05 was considered significant. Adobe Photoshop software was used for image acquisition. If necessary, only brightness and/or contrast were changed simultaneously for all areas of any blot.

Conflict of interest
The authors declare no conflict of interest.

Acknowledgements. We thank Ute Götäbl-Armbrust and Hartmut Kleinert for providing doxorubicin, caspase inhibitors and SP600125. Financial support (to SH) came from the University Medical Center Mainz and the German Research Foundation (DFG-grant HO3929/4-1).

1. Zhang K, Kaufman RJ. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 2008; 66 (2 Suppl 1): S102–S109.
2. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 2004; 4: 966–977.
3. Ogumori S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004; 11: 381–389.
4. Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest 2008; 118: 3378–3389.
5. Ott M, Goyvardz V, Orrenius S, Zhivotovsky B. Apoptosis and mitophagy. J Biol Chem 2010; 285: 29491–29500.

11. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. If necessary, only brightness and/or contrast were changed simultaneously for all areas of any blot.
12. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M et al.
13. Teiber JF, Horke S, Haines DC, Chowdhary PK, Xiao J, Kramer GL et al.
14. Shih DM, Lusis AJ. The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol 2009; 20: 288–292.
15. Shih DM, Xiao YR, Wang XP, Wang SS, Bouroud N, Fogelman AM et al. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res 2007; 100: 1200–1207.
16. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284–287.
17. Ng CJ, Bouroud N, Grijalva V, Hama S, Shih DM, Navab M et al. Paraoxonase 2 deficiency aggravates arteriosclerosis in mice despite lower apolipoprotein-B containing lipoprotein, anti-atherogenic role for paraoxonases. J Biol Chem 2006; 281: 29491–29500.